Abstract
Background: During last years, DNA vaccine immunogenicity has been optimized by the employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation prompted to osteopenia in mice.
Objective: The present study provides additional evidences about the proteinaceous adjuvants action within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity on marrow niches.
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with disrupted cytokine/chemokine production.
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow elements.
Keywords: Bone marrow, Bone marrow niche, Osteopenia, DNA vaccines, Adjuvants, Protein aggregates.
Current Gene Therapy
Title:Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis
Volume: 17 Issue: 5
Author(s): Maria Giovanna Sabbieti, Giovanna Lacava, Andrea Amaroli, Luigi Marchetti, Roberta Censi, Piera Di Martino and Dimitrios Agas*
Affiliation:
- School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino (MC),Italy
Keywords: Bone marrow, Bone marrow niche, Osteopenia, DNA vaccines, Adjuvants, Protein aggregates.
Abstract: Background: During last years, DNA vaccine immunogenicity has been optimized by the employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation prompted to osteopenia in mice.
Objective: The present study provides additional evidences about the proteinaceous adjuvants action within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity on marrow niches.
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with disrupted cytokine/chemokine production.
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow elements.
Export Options
About this article
Cite this article as:
Sabbieti Giovanna Maria , Lacava Giovanna , Amaroli Andrea , Marchetti Luigi , Censi Roberta , Di Martino Piera and Agas Dimitrios *, Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis, Current Gene Therapy 2017; 17 (5) . https://dx.doi.org/10.2174/1566523218666180105122626
DOI https://dx.doi.org/10.2174/1566523218666180105122626 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Nucleic-Acid Delivery Using Lipid Nanocapsules
Current Pharmaceutical Biotechnology Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Preface
Current Pharmaceutical Design COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses ACKNOWLEDGEMENTS TO REVIEWERS
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) <sup>1</sup>H and <sup>13</sup>C NMR Spectral Data of Neolignans Isolated from <i>Piper</i> Species
Current Organic Chemistry African Non Human Primates Infected by SIV - Why Dont they Get Sick? Lessons from Studies on the Early Phase of Non-Pathogenic SIV Infection
Current HIV Research State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member
Current Protein & Peptide Science Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Targeting the Histamine H4 Receptor: Future Drugs for Inflammatory Diseases
Current Organic Chemistry Acknowledgements to Reviewers
Recent Patents on Inflammation & Allergy Drug Discovery The Immunological Function of iGb3
Current Protein & Peptide Science Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research